A pancreas transplant places a whole donor pancreas into the recipient to restore insulin production in type 1 diabetes. The three categories are SPK (simultaneous pancreas-kidney), PAK (pancreas after kidney), and PTA (pancreas alone). SPK has the best outcomes at 80 to 90 percent graft survival at 1 year. Surgical and immunosuppression risks are significant, so the procedure is reserved for T1D with severe complications.
What a Pancreas Transplant Is
A pancreas transplant is a major abdominal surgery in which a whole donor pancreas — along with a small attached segment of duodenum — is implanted into the recipient. The recipient’s own pancreas is generally left in place (it still produces digestive enzymes; only the endocrine function fails in T1D). The transplanted pancreas connects to the recipient’s vasculature and drains either into the bladder or the small intestine.
Once perfused, the donor pancreas begins secreting insulin into the systemic circulation, restoring glucose-responsive endogenous insulin production.
The Three Categories
| Type | Stands for | Indication | Approx. share of US cases |
|---|---|---|---|
| SPK | Simultaneous pancreas-kidney | T1D with end-stage renal disease | ~75% |
| PAK | Pancreas after kidney | T1D with existing kidney transplant | ~15% |
| PTA | Pancreas transplant alone | T1D with severe hypoglycemia, preserved kidney function | ~10% |
Surgical Procedure
- General anesthesia, 4 to 8 hour operation
- Incision in the lower abdomen (often midline)
- Donor pancreas and attached duodenum placed in the iliac fossa
- Arterial and venous anastomoses to iliac vessels (or portal vein for systemic drainage variants)
- Exocrine drainage — enteric (to small intestine, most common) or bladder (older technique, still used selectively)
- For SPK, donor kidney typically placed on the contralateral side
- ICU monitoring 1 to 3 days, total hospital stay 1 to 2 weeks
Who Qualifies
- Type 1 diabetes (most common); rarely type 2 with insulin dependence
- End-stage renal disease or eGFR below 20-30 (for SPK)
- Existing kidney transplant (for PAK)
- Severe hypoglycemia, hypoglycemia unawareness, or extreme glycemic instability (for PTA)
- Age typically under 55 (though many centers will evaluate older candidates)
- Adequate cardiac and pulmonary function for major surgery
- No active infection, recent malignancy, or substance use disorder
- BMI typically below 32-35 (varies by center)
- Adherence support for complex lifelong medication regimen
Outcomes by Category
| Outcome | SPK | PAK | PTA |
|---|---|---|---|
| 1-year pancreas graft survival | ~85-90% | ~70-80% | ~60-70% |
| 5-year pancreas graft survival | ~65-75% | ~50-60% | ~35-50% |
| 1-year patient survival | ~95-97% | ~95% | ~95-97% |
| 5-year patient survival | ~88-92% | ~85-90% | ~90-92% |
| Insulin independence at 1 year (functioning graft) | Near 100% | Near 100% | Near 100% |
SPK has the best outcomes because rejection of the simultaneously transplanted kidney is easier to monitor (creatinine rises), allowing earlier detection of immune-mediated graft injury. PTA recipients rely on indirect markers (lipase, glucose) that flag rejection later.
Surgical Risks
- Bleeding requiring transfusion or reoperation
- Graft thrombosis — most common cause of early graft loss
- Anastomotic leak (intestinal or bladder)
- Infection — wound, intra-abdominal, urinary
- Pancreatitis of the graft
- Acute rejection — typically treated with steroids or anti-thymocyte globulin
- Chronic rejection
- Hypoglycemia (rare; usually as graft fails)
- Reoperation rate ~15-25% in first year
Immunosuppression
Lifelong immunosuppression is required. Typical regimens:
- Induction: anti-thymocyte globulin, basiliximab, or alemtuzumab at transplant
- Maintenance: tacrolimus + mycophenolate + corticosteroid (often tapered or eliminated)
- Alternative: tacrolimus + sirolimus combinations in selected patients
Immunosuppression side effects:
- Infection susceptibility (bacterial, viral, fungal, opportunistic)
- Malignancy risk — especially skin cancers and PTLD (post-transplant lymphoproliferative disease)
- Kidney injury (tacrolimus is nephrotoxic — particularly concerning for PTA recipients with intact native kidneys)
- Hypertension
- Hyperlipidemia
- New-onset diabetes after transplantation (NODAT) — paradoxical but real
- Bone loss
- Drug interactions
Pancreas Transplant Versus Islet Transplant
| Feature | Pancreas transplant | Islet transplant |
|---|---|---|
| Procedure | Open abdominal surgery, 4-8 hours | Catheter infusion, 30-60 minutes |
| Hospital stay | 1-2 weeks | 2-5 days |
| Surgical risk | Higher | Lower |
| 1-year insulin independence (with functioning graft) | ~80-90% (SPK) | ~50-70% |
| 5-year insulin independence | ~60-75% (SPK) | ~25-50% |
| Repeat procedures | Possible (rare) | Often needed (2-3 infusions) |
| Donor organs needed | 1 | 1-3 per recipient |
See islet cell transplant for more detail.
Waiting Times
In the US, median waiting times for SPK are typically 1 to 3 years; for PAK 1 to 2 years; for PTA, often shorter because the pool of suitable candidates is smaller. Times vary substantially by region, blood type, and center. UNOS maintains the national waitlist.
Cost
Pancreas transplant total costs (initial procedure plus first-year care) typically run $300,000 to $500,000 for PTA and $400,000 to $600,000 or more for SPK in the US. Insurance and Medicare coverage is established for both indications. Ongoing immunosuppression costs an additional $10,000 to $30,000+ per year, often partly covered through Medicare Part B for transplant immunosuppression.
Where Pancreas Transplant Fits in T1D Care
Pancreas transplant is one of several emerging or established T1D therapies. Related approaches include islet cell transplant, teplizumab, verapamil, and stem cell therapy. For broader context see treatment, A1C levels, and complications and related conditions.
Open Questions
- Long-term durability of grafts beyond 15 to 20 years
- Whether stem-cell-derived pancreas tissue could eventually replace donor pancreas needs
- Optimal immunosuppression minimization strategies
- Role of pancreas transplant for type 2 diabetes with insulin dependence (currently limited)
- How emerging cellular therapies will reshape candidate selection
What to Discuss with a Transplant Center
- Diabetes complications status — kidney function, retinopathy, neuropathy, cardiovascular
- Frequency and severity of hypoglycemia
- Cardiac and pulmonary fitness for surgery
- Insurance and financial coverage of long-term immunosuppression
- Support system for postoperative recovery and lifelong adherence
- Trade-offs versus islet transplant and other emerging therapies
The Bottom Line
A pancreas transplant restores endogenous insulin production in type 1 diabetes through major abdominal surgery placing a whole donor organ in the recipient. SPK (simultaneous pancreas-kidney) has the best outcomes at 80 to 90 percent pancreas graft survival at 1 year. PAK and PTA outcomes are somewhat lower. Surgical risks include bleeding, thrombosis, and rejection; lifelong immunosuppression carries infection, kidney, and malignancy risks. The procedure is reserved for T1D with severe complications — most commonly kidney failure or severe hypoglycemia. Talk to a transplant center if your T1D has progressed to end-stage renal disease or you have intractable hypoglycemia despite optimized insulin and CGM use.
